Summit Therapeutics Inc (NASDAQ:SMMT) shares, rose in value on Wednesday, July 09, with the stock price up by 7.61% to the previous day’s close as strong demand from buyers drove the stock to $24.74.
Actively observing the price movement in the last trading, the stock closed the session at $22.99, falling within a range of $23.23 and $25.05. The value of beta (5-year monthly) was -1.048. Referring to stock’s 52-week performance, its high was $36.91, and the low was $7.41. On the whole, SMMT has fluctuated by 20.16% over the past month.
With the market capitalization of Summit Therapeutics Inc currently standing at about $18.37 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-01.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SMMT’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of SMMT currently trading nearly 15.98% and 8.79% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.70, while the 7-day volatility ratio is showing 10.39% which for the 30-day chart, stands at 6.91%. Furthermore, Summit Therapeutics Inc (SMMT)’s beta value is -1.07.
A comparison of Summit Therapeutics Inc (SMMT) with its peers suggests the former has fared considerably weaker in the market. SMMT showed an intraday change of 7.61% in last session, and over the past year, it grew by 38.64%%.
Data on historical trading for Summit Therapeutics Inc (NASDAQ:SMMT) indicates that the trading volumes over the past 10 days have averaged 5.07 and over the past 3 months, they’ve averaged 5.19 million. According to company’s latest data on outstanding shares, there are 741.61 million shares outstanding.
Nearly 84.99% of Summit Therapeutics Inc’s shares belong to company insiders and institutional investors own 13.16% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 30.53 million shares as on 2025-06-13, resulting in a short ratio of 6.45. According to the data, the short interest in Summit Therapeutics Inc (SMMT) stood at 2617.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 25.73 million. The stock has risen by 241.71% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SMMT stock heading into the next quarter.
